Grade My Investments
HomeFree Stock Grades › NVAX

Novavax, Inc. (NVAX) Stock Grade

NVAX · Healthcare

A+
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$1.1B
P/E Ratio
2.5
Revenue Growth (YoY)
+64.7%
Net Margin
39.2%
Return on Equity
Dividend Yield
None

About Novavax, Inc.'s fundamentals

Novavax generates strong revenue growth at 64.7% year-over-year and maintains an impressive net profit margin of 39.2%, indicating efficient conversion of sales into earnings. The company's P/E ratio of 2.5 suggests it is trading at a low valuation multiple relative to current earnings. With a market capitalization of $1.1 billion and no dividend payment, the company appears to be reinvesting profits into operations rather than returning capital to shareholders.

Track NVAX free — no credit card required. Live grade + monthly AI report →